Cargando…
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
BACKGROUND: In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC) molecular subtypes in routine clinical care of a specialized BCU. METHODS:...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024419/ https://www.ncbi.nlm.nih.gov/pubmed/27634735 http://dx.doi.org/10.1186/s12885-016-2766-3 |
_version_ | 1782453795183132672 |
---|---|
author | Hennigs, André Riedel, Fabian Gondos, Adam Sinn, Peter Schirmacher, Peter Marmé, Frederik Jäger, Dirk Kauczor, Hans-Ulrich Stieber, Anne Lindel, Katja Debus, Jürgen Golatta, Michael Schütz, Florian Sohn, Christof Heil, Jörg Schneeweiss, Andreas |
author_facet | Hennigs, André Riedel, Fabian Gondos, Adam Sinn, Peter Schirmacher, Peter Marmé, Frederik Jäger, Dirk Kauczor, Hans-Ulrich Stieber, Anne Lindel, Katja Debus, Jürgen Golatta, Michael Schütz, Florian Sohn, Christof Heil, Jörg Schneeweiss, Andreas |
author_sort | Hennigs, André |
collection | PubMed |
description | BACKGROUND: In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC) molecular subtypes in routine clinical care of a specialized BCU. METHODS: The study was a prospectively single-center cohort study of 4102 female cases with primary, unilateral, non-metastatic breast cancer treated between 01 January 2003 and 31 December 2012. The five routinely used molecular subtypes (Luminal A-like, Luminal B/HER2 negative-like, Luminal B/HER2 positive-like, HER2-type, Triple negative) were analyzed. The median follow-up time of the whole cohort was 55 months. We calculated estimates for local control rate (LCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and relative overall survival (ROS). RESULTS: Luminal A-like tumors were the most frequent (44.7 %) and showed the best outcome with LCR of 99.1 % (95 % CI 98.5; 99.7), OS of 95.1 % (95 % CI 93.7; 96.5), and ROS of 100.0 % (95 % CI 98.5; 101.5). Triple negative tumors (12.3 %) presented the poorest outcome with LCR of 89.6 % (95 % CI 85.8; 93.4), OS of 78.5 % (95 % CI 73.8; 83.3), and ROS of 80.1 % (95 % CI 73.8; 83.2). CONCLUSIONS: Patients with a favorable subtype can expect an OS above 95 % and an LCR of almost 100 % over 5 years. On the other hand the outcome of patients with HER2 and Triple negative subtypes remains poor, thus necessitating more intensified research and care. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2766-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5024419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50244192016-09-20 Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study Hennigs, André Riedel, Fabian Gondos, Adam Sinn, Peter Schirmacher, Peter Marmé, Frederik Jäger, Dirk Kauczor, Hans-Ulrich Stieber, Anne Lindel, Katja Debus, Jürgen Golatta, Michael Schütz, Florian Sohn, Christof Heil, Jörg Schneeweiss, Andreas BMC Cancer Research Article BACKGROUND: In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC) molecular subtypes in routine clinical care of a specialized BCU. METHODS: The study was a prospectively single-center cohort study of 4102 female cases with primary, unilateral, non-metastatic breast cancer treated between 01 January 2003 and 31 December 2012. The five routinely used molecular subtypes (Luminal A-like, Luminal B/HER2 negative-like, Luminal B/HER2 positive-like, HER2-type, Triple negative) were analyzed. The median follow-up time of the whole cohort was 55 months. We calculated estimates for local control rate (LCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and relative overall survival (ROS). RESULTS: Luminal A-like tumors were the most frequent (44.7 %) and showed the best outcome with LCR of 99.1 % (95 % CI 98.5; 99.7), OS of 95.1 % (95 % CI 93.7; 96.5), and ROS of 100.0 % (95 % CI 98.5; 101.5). Triple negative tumors (12.3 %) presented the poorest outcome with LCR of 89.6 % (95 % CI 85.8; 93.4), OS of 78.5 % (95 % CI 73.8; 83.3), and ROS of 80.1 % (95 % CI 73.8; 83.2). CONCLUSIONS: Patients with a favorable subtype can expect an OS above 95 % and an LCR of almost 100 % over 5 years. On the other hand the outcome of patients with HER2 and Triple negative subtypes remains poor, thus necessitating more intensified research and care. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2766-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-15 /pmc/articles/PMC5024419/ /pubmed/27634735 http://dx.doi.org/10.1186/s12885-016-2766-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hennigs, André Riedel, Fabian Gondos, Adam Sinn, Peter Schirmacher, Peter Marmé, Frederik Jäger, Dirk Kauczor, Hans-Ulrich Stieber, Anne Lindel, Katja Debus, Jürgen Golatta, Michael Schütz, Florian Sohn, Christof Heil, Jörg Schneeweiss, Andreas Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
title | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
title_full | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
title_fullStr | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
title_full_unstemmed | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
title_short | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
title_sort | prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024419/ https://www.ncbi.nlm.nih.gov/pubmed/27634735 http://dx.doi.org/10.1186/s12885-016-2766-3 |
work_keys_str_mv | AT hennigsandre prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT riedelfabian prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT gondosadam prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT sinnpeter prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT schirmacherpeter prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT marmefrederik prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT jagerdirk prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT kauczorhansulrich prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT stieberanne prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT lindelkatja prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT debusjurgen prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT golattamichael prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT schutzflorian prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT sohnchristof prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT heiljorg prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy AT schneeweissandreas prognosisofbreastcancermolecularsubtypesinroutineclinicalcarealargeprospectivecohortstudy |